肥満と減量療法のジャーナル

抽象的な

The Dietary Supplement EGCG: NOPE(N-Oleyl- Phosphatidyletathanolamine and pigallocatechin-3-Gallato Formula)Helps Patients to Follow a Flexible Dietary Regimen and Induces Loss of Weight in Patients who had Previously Experienced No Response to Other Weight Loss Intervention

Daniele Barbar, Anna Menasci, Barbara Baldini, Cristina Pasquini and Paola Lapi

Background and aims:Obesity is increasing in all countries. The aim of this study was that of evaluating if the treatment with the dietary supplement ( N-oleyl-phstatidylethanolamine and epigallocatechin-3-gallato formula, EGCG-NOPE) could help patients to follow a flexible dietary regimen.

Methods:38 patients (20 males, 18 females, BMI 32-41, aged 33-72 years) were enrolled consecutively. These patients were subjects who had experienced no loss of weight during an intervention program consisting of a short training period, aimed at behaviour modification, followed by a dietary program based on rules of diet, without a fixed amount of calories. These patients were instructed to take EGCG-NOPE, two capsules (EGCG 120 mg and NOPE170 mg each capsule) at 1 hour before lunch and dinner, for two months. The study had a crossover design, and after two months EGCG-NOPE was stopped, the patients continuing to follow only the prescribed dietary rules. After a further two months, patients again took EGCG-NOPE for two more months. The primary end-point of the study was weight loss and a decrease in hip circumference, while the secondary end-point involved metabolic parameters: serum glucose, Homeostasis Model Assessment (HOMA) index, serum LDL and HDL cholesterol and triglycerides.

Results: After two months of treatment with EGCG-NOPE, the weight loss was 2.42kg+/-0.3 (p<0.001), and the decrease in hip circumferences was 2.0 cm +/- 0.2 (p<0.001).There was also a decrease in serum glucose (0.083 mm/L p<0.001), HOMA index (0.48 p<0.001), serum LDL cholesterol (0.46 mm/L p< 0.01), and serum triglycerides (0.25 mm/L p<0.001). HDL cholesterol increased by 0.20 mm/L (p<0.01). Following the two months without treatment, the weight and hip circumference were steady. After the next two months of treatment, the patients had a further loss of weight (2.10 kg +/-0.4 p < 0.01) and a further decrease in hip circumference (2.0 +/- 0.1 p < 0.001).

Conclusions: EGCG-NOPE, at these doses, has shown that it is capable of decreasing the body weight and hip circumferences in patients who had failed to lose weight during a previous dietary regimen. The improvement in the metabolic parameters during treatment with EGCG-NOPE represents a further aspect of paramount importa